Abstract

Aim: The aim of the study is to examine whether the combination of metformin+ glimepiride is superior to metformin mono therapy to treat the newly diagnosed type 2 DM patients to control the HbA1C and dyslipidaemia in terms of LDL, total cholesterol, TG etc. Materials and Methods: A Prospective randomised study with four groups. The control comprises of 60 healthy volunteers. 120 newly diagnosed type 2 DM cases (Group 1) were enrolled in the study. These 120 patients were randomised into two groups; Group 2 with 60 patients to receive Metformin and Group 3 with 60 patients to receive Metformin + glimepiride combination. Both the Group 2 and Group 3 have received the same hypolipidemic and antihypertensive drugs. Results: After about 4 years of treatment, in Group 2 and Group 3, FPG, HbA1C% and lipid profile were improved significantly (p Conclusion: Metformin and Glimepiride combination therapy improves HbA1c, LDL-C, HDL-C more effectively. However, Group 2 patients had shown better AIP than Group 3 patients. Keywords: Monotherapy, Combination therapy, Glycaemic control, Dyslipidemia, Atherogenesis.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.